SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.99% Passive Stake in Assembly Biosciences

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.99% in Assembly Biosciences, Inc. as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons,' have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership of Common Stock in ASSEMBLY BIOSCIENCES, INC.
• As of December 31, 2024, the Reporting Persons collectively beneficially own 316,084 shares of Assembly Biosciences, Inc. Common Stock.
• This ownership represents 4.99% of the issuer's class of securities.
• Armistice Capital, LLC, a Delaware entity, is an investment adviser, and Steven Boyd, a U.S. citizen, is identified as a parent holding company and individual.
• The shares are held with shared voting power and shared dispositive power, with no sole voting or dispositive power.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares, and exercises voting and investment power over these securities.
• Steven Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities held by the Master Fund.

Sentiment

Score: 5

Explanation: The document is a neutral, factual disclosure of beneficial ownership and does not contain information that would inherently suggest positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

This filing is a standard regulatory disclosure of beneficial ownership by an investment firm and its principal. It indicates a passive investment stake in Assembly Biosciences, Inc., which is common practice for institutional investors who hold positions below the 5% threshold that would trigger a more active Schedule 13D filing.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant passive institutional ownership, which can influence market perception and liquidity.
• Investment Professionals: Offers data points for tracking institutional investor activity and ownership trends in Assembly Biosciences, Inc.

Key Dates

Keywords

Assembly Biosciences, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Passive Investment, SEC Filing